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Abstract
Background: Although mechanical ventilation (MV) is a major supportive therapy for patients with acute
respiratory distress syndrome, it may result in side effects including lung injury. In this study we hypothesize that
MMP-9 inhibition by doxycycline might reduce MV-related lung damage. Using a proteomic approach we
identified the pulmonary proteins altered in high volume ventilation-induced lung injury (VILI). Forty Wistar rats
were randomized to an orally pretreated with doxycycline group (n = 20) or to a placebo group (n = 20) each of
which was followed by instrumentation prior to either low or high tidal volume mechanical ventilation. Afterwards,
animals were euthanized and lungs were harvested for subsequent analyses.
Results: Mechanical function and gas exchange parameters improved following treatment with doxycycline in the
high volume ventilated group as compared to the placebo group. Nine pulmonary proteins have shown significant
changes between the two biochemically analysed (high volume ventilated) groups. Treatment with doxycycline
resulted in a decrease of pulmonary MMP-9 activity as well as in an increase in the levels of soluble receptor for
advanced glycation endproduct, apoliporotein A-I, peroxiredoxin II, four molecular forms of albumin and two
unnamed proteins. Using the pharmacoproteomic approach we have shown that treatment with doxycycline leads
to an increase in levels of several proteins, which could potentially be part of a defense mechanism.
Conclusion: Administration of doxycycline might be a significant supportive therapeutic strategy in prevention of
VILI.
Background
Acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS), are characterized
by an acute inflammation and disruption of the alveolar-
capillary membranes leading to alveolar flooding with
protein-rich edema fluid. Mortality rates resulting from
ALI and ARDS range from 18 to 54.7% [1]. Although
mechanical ventilation (MV) is an important supportive
strategy for patients with ARDS, it is also known to
further lung injury in certain conditions of mechanical
stress, leading to ventilation-induced lung injury (VILI).
The mechanisms by which conventional MV exacerbates
lung injury and inflammation are of considerable clinical
significance. The potential importance of VILI in the
clinical treatment of critically ill patients has been well
established by recent clinical trials [2,3], where a relative
risk reduction of 22% in patients ventilated with the
lower tidal volume has been shown. The results from
these studies indicate that mortality attributable to VILI
is at least 9 to 10% in such patients. Therefore, despite
the significant progress that has been recently made in
emergency medicine, further research concerning the
pathophysiology of ALI is needed in order to indicate
new therapeutic targets preventing pulmonary damage.
Several experimental and clinical studies led to the
hypothesis that the deleterious effects of MV might be
mediated by local inflammation and the systemic release
of inflammatory cytokines (biotrauma) [4-6]. During
ALI/ARDS, various proinflammatory cytokines and che-
mokines are up-regulated and contribute to the
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In clinical studies, changes in levels of biological mar-
kers have been used primarily in an effort to identify
VILI rather than to study disease pathogenesis. The ven-
tilator-associated changes in levels of some biological
markers have been correlated with patient outcomes,
including duration of MV, organ failures, length of hos-
pital stay, and mortality [7-9]. Despite various pharma-
cologic interventions developed in the last two decades
that aim at specific targets, such as cytokines and adhe-
sion molecules, the therapeutic strategy for this syn-
drome remains to be established. Although alveolar
epithelial injury is a major determinant of outcome in
patients with ALI, there is still no reliable biological
marker of alveolar epithelial injury.
Recently, new mechanisms in the pathology of acute
respiratory failure have shifted the focus to lung
mechanics, tissue damage, remodeling, and the sys-
temic effects derived from the mechanical stress
imposed by the ventilator in patients with ARDS [7].
The conversion of physical signals such as contractile
forces or external mechanical perturbations into che-
mical signaling events is a fundamental cellular process
that occurs at the cell-extracellular matrix contact,
known as focal adhesions, thus modifying cell viscoe-
lastic properties, which may compromise the balance
of forces in the alveolar epithelium [10]. Stretch-
induced cell stiffening could compromise the balance
of forces at the cell-cell and cell-matrix adhesions [4].
Mascarenhas et al. [11] in an in vitro study showed
that de novo synthesis of hyaluronate in the extracellu-
lar matrix increases proinflammatory cytokines in VILI.
Moreover, Taylor et al. [12] demonstrated that hyaluro-
nate released after lung injury can stimulate endothelial
cells to produce cytokines by activation of a Toll-like
receptor 4-dependent mechanism, thus suggesting that
endogenous components of the extracellular matrix
can stimulate endothelial cells to trigger recognition of
injury in the initial stages of the wound defense and
repair response. Recent data from studies performed
on pulmonary microvascular endothelial cells and iso-
lated perfused rat lungs confirm the role of endothelial
responses to stretch-inducing VILI [13]. High tidal
volume ventilation (HVV) may induce focal adhesion
formation and recruit leukocytes on the endothelial
cells [14]. Haseneen and colleagues [13] demonstrated
the existence of a connection between stretched
endothelial cells and lung remodeling by release of
matrix metalloproteinases (MMPs) activated through a
membrane type-1 MMP (MT1-MMP) mechanism. The
first evidence suggesting that MMPs are important in
regulation of endothelial permeability was revealed by
Soccal and co-workers using a lung ischemia/reperfu-
sion (I/R) model [15]. Furthermore, it has been shown
that inhibition of MMP-2 and MMP-9 protects the
blood-brain barrier during cerebral ischemia and that
t h e r ei sa ni n c r e a s ei nM M P - 2a c t i v i t yr e s u l t i n gf r o m
an increase in oxidative stress [16]. In ALI, and mainly
in ARDS, increased levels of MMP-2 and MMP-9 in
the bronchoalveolar lavage (BAL) have been suggested
to play a role in basement membrane disruption [17].
Studies in various lung injury models show that MMPs
are strongly related to the pathogenesis of lung injury
[18-20] and that MMP inhibitors (MMPI) decrease the
extent of lung injury [21,22]. Therefore, understanding
the extracellular as well as intracellular actions of
MMPs might be crucial for studying molecular
mechanisms of ALI, including those related to MV.
The detrimental role of increased MMP-9 activity in
pathogenesis of VILI has been widely explored
[21,23-25] and there is also some evidence regarding
the beneficial role of doxycycline in other models of
ALI [26,27]. However, it has not been clearly estab-
lished whether doxycycline, by inhibition of MMP-9,
might play a beneficial role in limitation of VILI.
A better understanding of pathological mechanisms of
ALI should help not only to alleviate the side effects of
mechanical forces, but also to develop new therapeutic
strategies. Moreover, it is necessary to develop potential
pharmacologic targets to modulate the molecular and
cellular effects of lung stretch to minimize the iatrogenic
consequences of MV.
In the present study, using the pharmacoproteomic
approach, we investigated the hypothesis that increased
MMP-9 activity, involved in VILI, results in changes in
pulmonary proteome, which could be minimized by
MMP-9 inhibition by use of doxycycline.
Examination of global changes in protein levels due to
VILI should provide new insights into the mechanisms
involved in lung damage. Furthermore, it should lead to
the development of novel therapeutic strategies as well
as in establishment of more precise and sensitive diag-
nostic markers.
Results
Effect of ventilation on mechanical function of lungs and
on gas exchange
Since treatment with doxycycline had no effect on either
mechanical function of lungs or on parameters of gas
exchange in low tidal volume ventilated lungs which
were present in high tidal volume ventilated (HVV)
lungs, we decided to perform biochemical analyses of
lungs from only HVV groups (Figure 1). We postulated
that HVV should result in changes similar in nature but
greater in magnitude as compared to those observed in
lungs ventilated with low tidal volume and therefore the
observed changes in lung function should be much
more pronounced.
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Page 2 of 13Treatment with doxycycline resulted in a significant
increase in lung compliance as compared to the placebo
HVV treated group (221.8 ± 5.4 ml/cm H2O vs.1 4 8 . 3±
5.4 ml/cm H2O in the placebo group, respectively, p =
0.028) which was comparable to levels observed in the
low volume ventilation groups (Figure 2A). The values
of blood pH in all subgroups remained at physiological
levels which is shown in Figure 2B.
High tidal volume ventilation following placebo
treatment resulted in significant worsening of gas
exchange as assessed by a decrease in PaO2 (159.6 ±
21.9 mmHg vs. 232 ± 18.1 mmHg in low ventilated
placebo group, respectively, p = 0.027) as well as an
increase in PaCO2 (52.4 ± 3.7 mmHg vs. 40.1 ± 3.6
mmHg in low ventilated placebo group, respectively, p
= 0.048). An impairment in gas exchange was reduced
by pretreatment with doxycycline (PaO2 =2 1 2 . 6±1 3 . 3
mmHg, p = 0.048 vs. PaO2 in placebo treated HVV
group and PaCO2 =3 9 . 6±3 . 7m m H gv s .P a C O 2 in
placebo treated HVV group, respectively) (Figure 2C
and 2D).
Analysis and identification of proteins in lung
homogenates separated by 2-DE
Approximately 220 protein spots were detected in each
gel (Figure 3). Using an arbitrary set sensitivity thresh-
old, based on minimum peak value sensitivity and a
noise filter level, only nine proteins have shown signifi-
cant changes between analyzed groups (Figure 4). The
results of densitometric analysis of protein spots from
lungs subjected to ventilation after pretreatment with
doxycycline as well as from placebo treated group are
shown in Figure 4. The levels of all 9 proteins were sig-
nificantly higher in the doxycycline treated HVV group
as compared to the placebo treated HVV group. The
results of protein identification by mass spectrometry
(MS) analysis are presented in Table 1 and the struc-
tural information for the peptides used for protein iden-
tification is shown in Additional file 1 - Table S1. We
have identified 9 proteins including: soluble receptor for
advanced glycation endproduct (sRAGE), Apoliporotein
A-I (ApoA-I), Peroxiredoxine II (Prx II) and four mole-
cular forms of albumin. Also, two protein spots were
identified as unnamed proteins.
Next, the analysis of correlations between protein
levels was performed in order to assess the relationships,
which might reflect a common pathophysiological path-
way leading to the changes in their levels. Positive, sta-
tistically significant correlations between levels of
identified proteins were observed and are presented in
Table 2.
Mechanical ventilation and MMP-9 activity
The activity of MMP-9 in lung homogenates in both
groups is shown in Figure 5. Treatment with doxycy-
cline decreased MMP-9 activity (475.2 ± 28.1 AU vs.
813.8 ± 119.5 AU in placebo treated HVV group,
respectively, p < 0.05).
Immunoblot analysis of identified proteins
Immunoblot analysis for ApoA-I, Prx II and sRAGE has
revealed significant increase in the levels of analyzed
proteins in the group treated with doxycycline as com-
pared to the placebo group (Figure 6). Loading control
is shown in Figure 6D.
Figure 1 Experimental protocol. Forty Wistar rats were randomized to an orally pretreated with doxycycline group (n = 20) or to a placebo
group (n = 20) each of which was followed by instrumentation prior to either low or high tidal volume mechanical ventilation. Afterwards,
animals were euthanized and lungs were harvested for subsequent analyses.
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Proteins play an important role in regulation of biologi-
cal systems; therefore, they are among the most com-
mon diagnostic and therapeutic targets in medicine.
Hence, studying changes in the proteome should lead to
the discovery of novel diagnostic markers and therapeu-
tic strategies. Ventilation induced lung injury (VILI) has
been shown to be associated with alteration of a broad
variety of proteins within lungs (such as IL8, nuclear
factor Nrf2, surfactant associated proteins A and D as
well as pro-B cell enhancing factor (PBEF)) [28-31]. In
this rat model of VILI, high tidal volume ventilation
(HVV) should result in changes similar in nature but
greater in magnitude as compared to those observed in
mechanically ventilated patients in emergency units.
We have shown that the use of doxycycline effectively
reduces changes in function of lungs ventilated
mechanically with high tidal volume and decreases
Figure 2 Changes in lung function dependent on ventilation volume as well as on treatment with doxycycline. A. Lung compliance in
four subgroups separated by volume of ventilation and by treatment with doxycycline or placebo. *p < 0.05 for indicated pairs respectively. B.
pH values in four subgroups separated by volume of ventilation and by treatment with doxycycline or placebo. C. Partial pressure of O2 in
arterial blood at the end of mechanical ventilation in four subgroups separated by volume of ventilation and by treatment with doxycycline or
placebo. *p < 0.05 for indicated pairs respectively. D. Partial pressure of CO2 in arterial blood at the end of mechanical ventilation in four
subgroups separated by volume of ventilation and by treatment with doxycycline or placebo. *p < 0.05 for indicated pairs respectively.
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affected protein spots while the numbers (beside the circles) identify the protein spots from quantitative analysis using PDQuest measurement
software (BioRad).
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0.05
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as we have demonstrated, treatment with doxycycline
results in up-regulation of several proteins which could
potentially explain observed minimization of the sus-
ceptibility of pulmonary tissue to VILI.
In this study, the proteins for which levels have signif-
icantly increased have been shown to play a protective
role in lung injury under various pathological condi-
tions. Therefore, treatment aimed at preventing their
alteration, such as hereby demonstrated with doxycy-
cline, could be considered as an important therapeutic
aim in limitation of VILI. We have observed significant
changes in concentrations of nine proteins identified by
mass spectrometry (MS) analysis (soluble receptor for
advanced glycation endproduct (sRAGE), apoliporotein
A-I (ApoA-I), peroxiredoxin II (Prx II), four molecular
forms of albumin and two unnamed proteins). Since the
antibodies for unnamed proteins identified by MS analy-
sis are commercially unavailable, and albumins consti-
tute a heterogeneous group of proteins with diverse
antigen specificity, we decided to analyze only three
recognized proteins by immunoblot (ApoA-I, sRAGE
and Prx II). Detected proteins were up-regulated in dox-
ycycline treated group which is thus consistent with the
2-DE results.
Our study reveals an increase in ApoA-I level in pul-
monary tissue after treatment with doxycycline. Since
ApoA-I overexpression has been demonstrated to play a
protective role in lipopolisacharide (LPS) induced sys-
temic inflammation and multiple organ damage in mice
[32], the increase in ApoA-I level, which we observed,
can thus play an important role in limitation of VILI as
well. ApoA-I could effectively protect against endotoxe-
mia and acute lung damage. The potential mechanism
might be related to inhibition of inflammatory cytokine
release from macrophages.
The next altered protein which we detected in our
experimental model of VILI is peroxiredoxin II (Prx II).
Our results indicate that treatment with doxycycline
prevents a decrease in levels of Prx II; therefore the
antioxidative capacity of pulmonary tissue might be
increased, which could result in lower susceptibility to
ventilation induced damage. Various Prx enzymes were
tested for their capacity to scavenge peroxynitrite. Some
of these enzymes were reported to catalytically reduce
peroxynitrite to nitrite rapidly enough to forestall the
damage of cellular components [33]. Subsequently, dif-
ferent Prx enzymes have been shown to be associated
with peroxynitrite reductase activity [34], mammalian
P r xV[ 3 5 ] ,a n dP r xV I[ 3 6 ] .T h ec h a n g ei nP r xI Il e v e l
in response to the treatment with doxycycline, observed
in this study, could be an important defense mechanism
limiting peroxynitrite-dependent lung damage during
mechanical ventilation.
Furthermore, this study demonstrates an increase in
the expression of soluble receptor for advanced glyca-
tion endproduct (sRAGE) due to pretreatment with dox-
ycycline. Recently, several carboxyl-terminal truncated
isoforms of RAGE, such as soluble RAGE (sRAGE) and
endogenous secretory RAGE (esRAGE) were identified
Table 1 Results of identification of protein spots changed by doxycycline treatment
Protein Spot (SSP) Protein Score Protein Score C.I. % Total Ion Score Total Ion C.I. % Protein Identification
1201 122 100 111 100 sRAGE
1202 621 100 537 100 Peroxiredoxin II
2202 436 100 400 100 Albumin, isoform CRA_b
2403 249 100 135 100 Unnamed protein
3202 511 100 452 100 Unnamed protein
3204 170 100 164 100 Albumin, isoform CRA_a
3401 1170 100 918 100 Apolipoprotein A-I
5402 883 100 701 100 Albumin
7704 1150 100 918 100 Serum Albumin
Table 2 Correlations between levels of identified protein
Proteins R= p=
sRAGE and Albumin 0.87 0.001
sRAGE and Albumin, isoform CRA_a 0.96 0.0001
sRAGE and Apolipotrotein A-I 0.72 0.029
Peroxiredoxin II and Serum albumin 0.86 0.005
Albumin and Albumin, isoform CRA_a 0.85 0.002
Albumin and Unnamed protein (SSP 2403) 0.73 0.022
Apolipoprotein A-I and Albumin, isoform CRA_a 0.67 0.049
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which is up-regulated in the alveolar space in response
to intratracheal LPS challenge, mitigates LPS-induced
inflammatory events in the lung, including neutrophil
infiltration, increased lung permeability, edema forma-
tion, production of inflammatory cytokines, and NF-kB.
These findings indicate that RAGE plays a critical role
in pathogenesis of lung injury and the blockade of
RAGE signaling by sRAGE could be protective against
the development of lung injury [38]. Moreover, sRAGE
may be a useful biological marker of alveolar epithelial
injury and impaired alveolar fluid clearance [39-45].
Two altered protein spots were identified as unnamed
proteins (SSP 2403: MW≈38kD, pI≈5.9 and SSP 3202:
MW≈28kD, pI≈6.2). The levels of both proteins were
significantly higher after pretreatment with doxycycline.
The exact role of these proteins in pulmonary pathology
remains unknown and needs to be further investigated.
In our study we also observed a decreased level of albu-
mins (albumin isoform CRA_a [NCBI:EDL88549], albu-
min [NCBI:NP_599153], serum albumin [NCBI:P02770]
and albumin isoform CRA_b [NCBI:EDL92173]) in the
placebo treated HVV group which could reflect protein
loss from the extracellular space within pulmonary tis-
sue as well as transudate of the albumin-poor fluid into
the extracellular space. The increase in albumin levels in
pulmonary tissue after doxycycline treatment might be
due the restoration of endothelial integrity in response
to MMP-9 inhibition resulting in limitation of fluid
transudation. However, further research is required in
order to elucidate whether this phenomenon plays a
role in pathogenesis of VILI or is only additional effect
of treatment with doxycycline.
Although the identified proteins are involved in differ-
ent regulatory mechanisms, there might be one common
mechanism leading to their alteration during pathology,
s i n c ep o s i t i v ec o r r e l a t i o n sw e r eo b s e r v e d .S i n c ei n h i b i -
tion of MMP-9 by doxycycline prevents protein altera-
tion during HVV, a degradation of these proteins by
MMP-9 might be postulated. Hence, treatment with
doxycycline could be an effective pharmacological inter-
vention attenuating this phenomenon and resulting in
decreased lung damage during mechanical ventilation.
Nevertheless, further research is required in order to
verify this hypothesis and to assess its relevance in clini-
cal practice.
Two studies identified elevated MMP-9 levels in the
lungs of newborns with acute respiratory distress syn-
drome [46,47]. Although these studies demonstrate that
elevated MMP-9 levels distinguish individuals with acute
Figure 5 Quantitative analysis of the MMP-9 activity with (+) and without (-) pretreatment with doxycycline. Inset is a representative
zymography gel. *p < 0.05
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Page 8 of 13Figure 6 Immunoblot analysis of proteins identified from 2-DE and mass spectrometry analysis. Lung samples from the groups treated
with doxycycline or with placebo were analyzed. A. ApoA-I – apolipoprotein A-I, B. Prx II – peroxiredoxin II, C. sRAGE – soluble receptor for
advanced glycation end-product. D. Loading control for immunoblots (Actin). *p < 0.05.
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whether differences in MMP-9 levels/activity have
pathophysiological or prognostic significance. In this
study we have shown for the first time that the use of
doxycycline in an animal model of a high volume VILI
not only decreases the MMP-9 activity but also prevents
alteration of nine proteins in pulmonary tissue. Thus,
decreasing MMP-9 activity by use of an MMP-inhibitor
may protect the lungs from VILI. However, the question
of whether the changes which we observed in the pul-
monary proteome in response to the treatment with
doxycycline are directly due to MMP-9 inhibition or
whether they are a result of other mechanisms of drug
action remains unanswered.
Conclusions
In conclusion, we found that treatment with doxycycline
prevents alteration of proteins which are shown to play
ap r o t e c t i v er o l ei nl u n gi n j u r y .M o r e o v e r ,w es h o w
positive correlations between their levels which might
reflect a common pathway of their alteration that is
effectively inhibited by use of doxycycline. Identified
proteins could be a proteolytic target for MMP-9 and
therefore the use of doxycycline as MMP-9 inhibitor
could prevent their degradation during high tidal
volume ventilation.
A better understanding of these pathologic mechan-
isms will help not only in alleviating the side effects of
mechanical forces but also in the development of new
therapeutic strategies. It is necessary to discover phar-
macologic targets to modulate the molecular effects of
lung stretch in order to minimize the negative conse-
quences of mechanical ventilation. Moreover, an effec-
tive therapy for these disorders needs to be instituted
during early stages of the disease, prior to the develop-
ment of extensive lung destruction and fibrosis.
Materials and methods
This study was carried out with the approval of the Ani-
mal Research Ethics Board of the University Committee
on Animal Care and Supply (University of Saskatche-
wan) and conformed to the principles embodied in the
Declaration of Helsinki.
Experimental protocol
Model of ventilation-induced lung injury
We studied two groups of twenty adult Wistar rats
(weight 357 ± 41 g) using a high volume ventilation pro-
tocol known to produce ventilation-induced lung injury
(VILI) [48] (Figure 1). All animals were pretreated orally
late in the day (at approximately 9 PM) prior to the pro-
cedure day. The first group of animals was given 2 mg/
kg of lactose as placebo (placebo treated HVV group)
and the second group was given 2 mg/kg of doxycycline
hyclate (Doxycin, RIVA Labs., Blainville, PQ, Canada)
(doxycycline treated HVV group). Next morning (at
approximately 7 AM) anesthesia was induced by intra-
peritoneal injection of sodium pentobarbital (60 mg/kg)
and was maintained by a continuous intravenous infu-
sion of sodium pentobarbital (25 mg/kg/h). The trachea
was then exposed and an endotracheal tube (13-15
gauges) inserted. The rat body temperature was moni-
tored by a rectal probe and body temperature was main-
tained near 37°C by a heating pad. A small animal
ventilator (Harvard rodent ventilator, Model 683, Har-
vard Apparatus, Holliston, Mass., USA) was connected
to the steel tracheal tube and all animals initially
received standardized ventilator settings (Tidal volume
(Vt) = 7.5 ml/kg, rate: 60 breaths/min; FiO2 = 1.0). Pres-
sure at the airway opening was measured using an air-
phase transducer (P45, Validyne Eng. Corp., Northridge,
CA) and continuously displayed. A catheter (25 gauges,
Insyte IV catheter, Benton Dickson, Sandy, Utah, USA)
was inserted into the carotid artery and systemic arterial
blood pressure was monitored throughout (Space
ALABS MODEL 510, Squibb, Hollsboro, OR). All ani-
mals received a continuous infusion of normal saline at
6 ml/kg/h as maintenance fluid. Two groups of animals
received 20 min of high volume ventilation (HVV) (Vt =
30 ml/kg, rate = 15/min, PEEP = 8 cm H2O). After the
20 min test ventilation all groups were ventilated further
for 240 min on the low volume regimen (Vt = 7.5 ml/
kg, rate = 60/min). During periods of HVV, the respira-
tory rate was decreased in order to maintain constant
minute ventilation and physiologic blood pH.
At the end of the ventilation period, 1 ml of arterial
blood was collected for gas analysis using a heparinized
syringe (CIBA-Corning 238 pH - Blood Gas Analyzer,
Midfield, Mass.). The pulmonary compliance was mea-
sured using the method described by LeSouef et al [49].
Afterwards, the animals were euthanized and lungs were
rapidly removed as a block. The lungs were rinsed/per-
fused for one minute with normal saline solution and
snap-frozen in liquid nitrogen for subsequent biochem-
ical analyses.
Lung Tissue Assays
Preparation of lung extracts
Protein samples for 2-dimensional electrophoresis (2-
DE) were prepared at room temperature by mixing fro-
zen (-80°C), powdered tissue (40 to 60 mg wet weight)
with 200 μL of rehydration buffer (8 mM urea, 4%
CHAPS, 10 mM DTT, 0.2% Bio-Lytes 3/10 [BioRad]).
Samples were sonicated twice for 5 s and centrifuged
for 10 min at 10 000 g at 4°C to remove any insoluble
particles. Protein content of the extract in rehydration
buffer was measured with the BioRad protein assay. For
other biochemical studies, frozen powdered tissue was
homogenized on ice in 50 mM Tris-HCl (pH 7.4) con-
taining 3.1 mM sucrose, 1 mM DTT, 10 μg/ml
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aprotinin and 0.1% Triton X-100. Homogenates were
centrifuged at 10 000 g at 4°C for 10 min and the super-
natant was collected and stored at -80°C until further
use.
Assessment of MMP-9 activity using zymography
Gelatin zymography was performed as described pre-
viously [50]. Briefly, lung extract preparations (60 μgo f
protein) were applied to 8% polyacrylamide gel copoly-
merized with 2 mg/ml gelatin. After electrophoresis,
gels were rinsed 3 times for 20 min each in 2.5% Triton
X-100 to remove SDS. The gels were then washed twice
in incubation buffer (50 mM Tris-HCl, 5 mM CaCl2,
150 mM NaCl, and 0.05% NaN3) for 20 min each at
room temperature and then incubated in incubation
buffer at 37°C for 24 h. The gels were stained in 0.05%
Coomassie Brilliant Blue G in a mixture of methanol:
acetic acid: water (2.5:1:6.5, v:v) and destained in aqu-
eous 4% methanol: 8% acetic acid (v:v). Developed gels
were scanned with a GS-800 densitometer (BioRad) and
the MMP-9 activity was measured using Quantity One
measurement software 4.6 (BioRad).
2-dimensional gel electrophoresis (2-DE)
After preparing the tissue extract, a protein solution (0.4
mg) was used to rehydrate a dried first-dimension strip
(IPG strip, pH 5-8, 11 cm, BioRad) for 18 h at 20°C
under mineral oil. Next, the strips were subjected to iso-
electrofocusing (IEF) using a BioRad Protean IEF cell
apparatus (BioRad) with focusing parameters as follows:
step 1: 15 min with end voltage at 250 V; step 2: 150
min with end voltage at 8000 V; step 3: 35000 V-hours
(approximately 260 min). After IEF, the strips were
reduced and alkylated in 1% DTT and 2.5% iodoaceta-
mide (in ReadyPrep 2DE Starter Kit Equilibration Buffer
I and II, respectively, BioRad). The proteins were sepa-
rated by size in the second dimension by SDS-PAGE on
8-16% Criterion precast gels (BioRad). To minimize var-
iations in resolving proteins during the 2-DE run, all
gels were run simultaneouslyu s i n gaC r i t e r i o nD o d e c a
Cell (BioRad). All the gels were stained in the same
Coomassie Brilliant Blue R 250 (BioRad) staining bath
as previously described [51].
Developed gels were scanned using a GS-800 cali-
brated densitometer (BioRad). The intensity of spots
from 2-DE gels was measured using PDQuest 7.1 soft-
ware (BioRad).
Mass spectrometry (MS) Analysis
Selected protein spots were manually excised from the
2-DE gels. These spots were then processed using a
MassPrep Station from Micromass using the methods
supplied by the manufacturer. Briefly, the excised gel
fragment containing the protein spot was first destained,
reduced, alkylated, digested with trypsin and extracted.
Mass analysis of the trypsin digest was performed on
MALDI-TOF Voyager DE-Pro from Applied Biosystems.
A mass deviation of 0.5 was tolerated and one missed
cleavage site was allowed. Resulting values from mass
spectrometry analysis for monoisotopic peaks were used
to search against the NCBInr and Swiss-Prot databases
with Ratus norvegicus specified. We used the Mascot
http://www.matrixscience.com search engine to search
the protein database for protein identification. The
Mowse scoring algorithm [52] was used for justification
of accuracy of protein identification and is incorporated
in the Mascot search engine.
Immunoblotting
We separated 30 μg of protein from each lung extract
u s i n gC r i t e r i o np r e - c a s tg e l s( 8t o1 6 % )( B i o R a d )a n d
transferred the protein to a polyvinylidene difluoride
membrane (Bio-Rad). Apolipoprotein A-I (ApoA-I) was
identified using a rabbit polyclonal anti-ApoA-I anti-
body (from Santa Cruz Biotechnology Inc.) at dilution
1:200 and a goat anti-rabbit IgG-HRP as secondary
antibody (from Santa Cruz Biotechnology Inc.) at dilu-
tion 1:4000. Peroxiredoxin II (Prx II) was identified
using a rabbit polyclonal anti-Prx II antibody (from
Santa Cruz Biotechnology Inc.) at dilution 1:200 and
goat anti-rabbit IgG-HRP as secondary antibody (from
Santa Cruz Biotechnology Inc.) at dilution 1:2000.
Soluble receptor for advanced glycosylation endproduct
(sRAGE) was identified using a goat polyclonal anti-
RAGE (N16) antibody against the N-terminus of
RAGE (from Santa Cruz Biotechnology Inc.) at dilution
1:200 and donkey anti-goat IgG-HRP as secondary
antibody (from Santa Cruz Biotechnology Inc.) at dilu-
tion 1:2000. Actin as a loading control was assessed
with a mouse anti-actin antibody (Millipore) at dilu-
tion 1:150 and goat anti-mouse IgG-HRP (BioRad) as
secondary antibody at dilution 1:1000. Bands detected
by chemiluminescence were scanned using VersaDoc
Gel Imaging System (BioRad) and measured by Quan-
tity One software 4.6 (BioRad).
Statistical analysis
The protein spot levels as well as MMP-9 activity were
evaluated by Mann-Whitney U-test and student’st - t e s t .
Functional data was analysed using Kruskal-Wallis test
followed by Dunns test for pairs. Correlations between
t h el e v e l so fp r o t e i n sw e r ea s s e s s e db yS p e a r m a n
Moment. Data are expressed as mean ± SEM. Differ-
ences were considered significant at p < 0.05.
Additional file 1: Table S1. Structural information of the peptides used
for protein identification
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-5956-8-3-
S1.PPT]
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